Afatinib/gefitinib/osimertinibAcquired resistance: 4 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1806卷 / 1期

关键词：

D O I：

10.1007/s40278-020-79039-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：21 / 21

相关论文

共 50 条

[1] Afatinib/gefitinib/osimertinibAcquired resistance: case report
Reactions Weekly, 2020, 1810 (1) : 18 - 18
[2] Afatinib/gefitinib/osimertinibAcquired resistance in non-small cell lung cancer: 2 case reports
Reactions Weekly, 2019, 1741 (1) : 16 - 16
[3] Afatinib/erlotinib/gefitinib/osimertinibAcquired drug resistance and transformation from adenocarcinoma to squamous cell carcinoma: 4 case reports
Reactions Weekly, 2020, 1803 (1) : 18 - 18
[4] Gefitinib/osimertinibAcquired drug resistance: 3 case reports
Reactions Weekly, 2023, 1948 (1) : 215 - 215
[5] Afatinib/osimertinibAcquired resistance and lack of efficacy: 2 case reports
Reactions Weekly, 2021, 1858 (1) : 20 - 20
[6] Erlotinib/gefitinib/osimertinibAcquired drug resistance: 2 case reports
Reactions Weekly, 2021, 1856 (1) : 201 - 201
[7] Erlotinib/gefitinib/osimertinibAcquired drug resistance: 3 case reports
Reactions Weekly, 2019, 1752 (1) : 158 - 158
[8] Gefitinib/osimertinibAcquired resistance and lack of efficacy: 2 case reports
Reactions Weekly, 2023, 1963 (1) : 260 - 260
[9] Afatinib/gefitinib/osimertinibDrug resistance: 3 case reports
Reactions Weekly, 2019, 1773 (1) : 18 - 18
[10] OsimertinibAcquired drug resistance: 4 case reports
Reactions Weekly, 2022, 1911 (1) : 340 - 340

← 1 2 3 4 5 →